Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares dropped 6% during trading on Wednesday . The company traded as low as $8.60 and last traded at $8.46. Approximately 139,382 shares changed hands during trading, an increase of 15% from the average daily volume of 121,502 shares. The stock had previously closed at $9.00.
Analyst Ratings Changes
Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating for the company.
Get Our Latest Analysis on GYRE
Gyre Therapeutics Stock Down 1.0%
The stock's 50-day moving average price is $9.08 and its 200 day moving average price is $10.21. The firm has a market cap of $749.13 million, a price-to-earnings ratio of 399.50 and a beta of 1.79.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.03 EPS for the quarter, meeting analysts' consensus estimates of $0.03. The business had revenue of $22.06 million during the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its position in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares during the last quarter. Bank of America Corp DE raised its position in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after purchasing an additional 1,996 shares in the last quarter. Advantage Alpha Capital Partners LP raised its position in Gyre Therapeutics by 54.0% in the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock worth $105,000 after purchasing an additional 4,790 shares in the last quarter. Bank of New York Mellon Corp raised its position in Gyre Therapeutics by 18.7% in the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock worth $127,000 after purchasing an additional 2,596 shares in the last quarter. Finally, Barclays PLC raised its position in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company's stock.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
